Next-gen psoriasis drug rivalry between Bristol Myers and Nimbus spills into a legal battle

When Bristol Myers Squibb decided to acquire Celgene for $80 billion in 2019, the two were forced to divest psoriasis drug Otezla to Amgen in order to avoid a monopoly in that market.

But it’s the rivalry over the next generation of psoriasis drugs between Bristol Myers and Nimbus Therapeutics that could turn into an anti-competitive monopoly, Nimbus alleges in a new lawsuit filed late last week.